EADV 2025 News: Investigational Temtokibart Performs Well in Phase 2b AD Study
Temtokibart, Leo Pharma’s investigational agent eczema drug, met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses in adults with moderate-to-severe atopic dermatitis (AD), according to a study presented at the 2025 European Academy of Dermatology and Venereology (EADV) Annual Meeting in Paris, France.